Physician profile
Steven Randall Mitchell
NPI 1821265091
$6,838.79
in general payments reported to CMS, 2019-2025
26 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,731 · 2020: $1,959 · 2021: $614 · 2022: $820 · 2023: $257 · 2024: $305 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $715.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $3,150.77 | 2019-2020 | |
| Abbvie INC. | $573.48 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $447.52 | 2019-2024 | Trintellix |
| Jazz Pharmaceuticals INC. | $344.96 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $341.34 | 2019-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $228.76 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $228.00 | 2019-2020 | |
| Corium, LLC | $201.20 | 2022-2024 | Azstarys |
| Janssen Pharmaceuticals, INC | $187.98 | 2019-2024 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $186.48 | 2022-2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $175.00 | 2019 | |
| Gilead Sciences, INC. | $138.07 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $115.47 | 2022-2024 | Caplyta |
| Bausch Health US, LLC | $79.53 | 2021-2022 | |
| Genentech USA, INC. | $74.73 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $55.17 | 2023-2025 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $51.36 | 2019-2022 | |
| Lilly USA, LLC | $44.51 | 2019 | |
| Avion Pharmaceuticals | $41.66 | 2021-2023 | Balcoltra |
| Idorsia Pharmaceuticals US INC | $39.43 | 2022-2023 | Quviviq |
| Alkermes, INC. | $33.80 | 2021-2022 | |
| Axsome Therapeutics, INC. | $30.73 | 2025 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $21.88 | 2021 | |
| Pfizer INC. | $19.22 | 2022 | |
| Neurocrine Biosciences, INC. | $16.37 | 2019 | |
| Agile Therapeutics, INC. | $11.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.